Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
NCT ID: NCT04598269
Last Updated: 2023-09-28
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-09-30
Study Completion Date
2021-04-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of participants with moderate or severe atopic dermatitis (AD).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
NCT05432596
Atopic Dermatitis
COMPLETED
PHASE2
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06585202
Atopic Dermatitis
COMPLETED
PHASE2
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706
Atopic Dermatitis
Atopic
Dermatitis
+2 more
RECRUITING
PHASE2
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
NCT03585296
Atopic Dermatitis
COMPLETED
PHASE2
A Study Evaluating TRIV-509 in Atopic Dermatitis
NCT07167758
Atopic Dermatitis
RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants underwent screening evaluations to determine eligibility up to 30 days prior to randomization. Participants who meet all the entry criteria were randomized on Day 1 to active or vehicle treatment. Participants applied study drug (ATI-1777 topical solution 2.0% w/w or vehicle) twice daily for 4 weeks with weekly study visits and were to return 2 weeks after the last dose of study medication for a Post treatment Follow-up (PTFU) Visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Atopic Dermatitis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Randomized, Double-blind, Vehicle-controlled, Parallel-group Study
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ATI-1777
ATI-1777 topical solution 2.0% w/w, twice daily
Group Type
EXPERIMENTAL
ATI-1777
Intervention Type
DRUG
ATI-1777 topical solution 2.0% w/w
Vehicle
Vehicle topical solution, twice daily
Group Type
PLACEBO_COMPARATOR
Vehicle
Intervention Type
DRUG
Vehicle topical solution containing no ATI-1777
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ATI-1777
ATI-1777 topical solution 2.0% w/w
Intervention Type
DRUG
Vehicle
Vehicle topical solution containing no ATI-1777
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Able to comprehend and willing to sign the IRB approved informed consent form (ICF) prior to administration of study-related procedures.
2. Male patients or non-pregnant, non-nursing female patients 18 to 65 years old, inclusive, at the time of informed consent.
3. Pregnancy and Contraception:
* Women of childbearing potential (WOCBP), must have a negative serum pregnancy test at the Screening Visit, a negative urine pregnancy test immediately prior to the first application of study medication on Day 1, and a negative urine pregnancy test at each study visit thereafter.
* WOCBP must agree to use 2 forms of highly effective contraception, including 1 physical barrier (condom or diaphragm) plus another highly effective method, such as adequate hormonal method (e.g., contraceptive implants, injectables, oral contraceptives) or nonhormonal methods (e.g., intrauterine device, spermicidals) throughout the Screening Period and until 30 days after the last administration of study medication.
* Male patients with partners of childbearing potential may be enrolled if they are:
* Documented to be surgically sterile (vasectomy), or
* Using 2 adequate forms of highly effective contraception, 1 of which should be a physical barrier until 90 days after the last administration of study medication.
4. Have a diagnosis of AD fulfilling the specified diagnostic criteria of Hanifin and Rajka (Hanifin and Rajka 1980).
5. Have at least a 6-month history of AD prior to the Screening Visit, and no significant AD flares for the 4 weeks prior to the Screening Visit.
6. Have at least 1 lesion that measures at least 3 cm2 at the Screening Visit and on Day 1 prior to the first dose of study medication. This lesion must be representative of the patient's disease state, but not located on the hands, feet, or genitalia.
7. Have a stable diagnosis of moderate or severe (IGA score 3 or 4) AD at the Screening Visit.
8. Have AD affecting 3% to 20% BSA (not including scalp, face, palms of hands, soles of feet, groin, and genitalia) at the Screening Visit.
9. Willing to refrain from washing area of treatment or swimming for 6 hours after each study medication application.
10. Willing to refrain from excessive sun exposure (e.g., sunbathing and/or tanning salon visits) and to minimize sun exposure (e.g., wear sun protective clothing, hat) as much as possible.
11. Willing to refrain from use of moisturizers, emollients, and sunscreen on AD study treatment areas for duration of protocol therapy.
12. Willing to refrain from participating in strenuous exercise that would cause profuse sweating for a period of 6 hours after each study medication application.
13. Willing to return to the clinic, follow all study instructions, attend all study visits, and complete study procedures.
14. In good general health and free of any known disease state or physical condition that, in the investigator's opinion, might impair evaluation of the patient or that might expose the patient to an unacceptable risk by study participation.
15. Willing and capable of taking appropriate coronavirus disease 2019 (COVID-19) risk mitigation precautions (e.g., wearing a mask in public, adhering to social distancing, etc.) as recommended or required by local, state, or federal guidelines during participation in the study.
2. Male patients or non-pregnant, non-nursing female patients 18 to 65 years old, inclusive, at the time of informed consent.
3. Pregnancy and Contraception:
* Women of childbearing potential (WOCBP), must have a negative serum pregnancy test at the Screening Visit, a negative urine pregnancy test immediately prior to the first application of study medication on Day 1, and a negative urine pregnancy test at each study visit thereafter.
* WOCBP must agree to use 2 forms of highly effective contraception, including 1 physical barrier (condom or diaphragm) plus another highly effective method, such as adequate hormonal method (e.g., contraceptive implants, injectables, oral contraceptives) or nonhormonal methods (e.g., intrauterine device, spermicidals) throughout the Screening Period and until 30 days after the last administration of study medication.
* Male patients with partners of childbearing potential may be enrolled if they are:
* Documented to be surgically sterile (vasectomy), or
* Using 2 adequate forms of highly effective contraception, 1 of which should be a physical barrier until 90 days after the last administration of study medication.
4. Have a diagnosis of AD fulfilling the specified diagnostic criteria of Hanifin and Rajka (Hanifin and Rajka 1980).
5. Have at least a 6-month history of AD prior to the Screening Visit, and no significant AD flares for the 4 weeks prior to the Screening Visit.
6. Have at least 1 lesion that measures at least 3 cm2 at the Screening Visit and on Day 1 prior to the first dose of study medication. This lesion must be representative of the patient's disease state, but not located on the hands, feet, or genitalia.
7. Have a stable diagnosis of moderate or severe (IGA score 3 or 4) AD at the Screening Visit.
8. Have AD affecting 3% to 20% BSA (not including scalp, face, palms of hands, soles of feet, groin, and genitalia) at the Screening Visit.
9. Willing to refrain from washing area of treatment or swimming for 6 hours after each study medication application.
10. Willing to refrain from excessive sun exposure (e.g., sunbathing and/or tanning salon visits) and to minimize sun exposure (e.g., wear sun protective clothing, hat) as much as possible.
11. Willing to refrain from use of moisturizers, emollients, and sunscreen on AD study treatment areas for duration of protocol therapy.
12. Willing to refrain from participating in strenuous exercise that would cause profuse sweating for a period of 6 hours after each study medication application.
13. Willing to return to the clinic, follow all study instructions, attend all study visits, and complete study procedures.
14. In good general health and free of any known disease state or physical condition that, in the investigator's opinion, might impair evaluation of the patient or that might expose the patient to an unacceptable risk by study participation.
15. Willing and capable of taking appropriate coronavirus disease 2019 (COVID-19) risk mitigation precautions (e.g., wearing a mask in public, adhering to social distancing, etc.) as recommended or required by local, state, or federal guidelines during participation in the study.
Exclusion Criteria
1. Unstable course of AD (spontaneously improving or rapidly deteriorating) based on the patient history or as determined by the investigator during the Screening Period.
2. Refractory AD (i.e., AD that required frequent hospitalizations and/or frequent intravenous treatment for skin infections within the year before the Screening Visit).
3. AD of a severity (EASI \>48) that the patient is not a candidate for a vehicle-controlled study.
4. Any signs or symptoms associated with AD therapy (e.g., history of anaphylaxis, hypersensitivity reactions, skin atrophy, striae, pigmentary changes) that, in the investigator's opinion, might impair evaluation of the AD or which exposes the patient to unacceptable risk by study participation.
5. Concomitant skin disease or clinically infected AD or presence of other skin disease in the area to be dosed that may interfere with study assessments.
6. Use of any of the following treatments within the indicated washout period prior to Day 1:
* Phototherapy (ultraviolet A, ultraviolet B, or psoralen and ultraviolet A therapy) within 4 weeks prior to Day 1.
* Systemic biologic immunosuppressant or immunomodulatory therapy (e.g., etanercept, alefacept, infliximab, dupilumab) within 12 weeks (or 5 half-lives of the product, whichever is longer) prior to Day 1.
* Non-biologic immunosuppressants (e.g., methotrexate, retinoids, calcineurin inhibitors, cyclosporine, hydroxycarbamide \[hydroxyurea\], azathioprine) within 4 weeks prior to Day 1.
* Janus kinase (JAK) inhibitors (systemic and topical) within 4 weeks prior to Day 1.
* Systemic corticosteroids within 2 weeks prior to Day 1 (intranasal, inhaled, and topical ocular corticosteroids are allowed).
* Cytostatic agents within 4 weeks prior to Day 1.
* Crisaborole within 2 weeks prior to Day 1.
* Systemic antibiotics within 30 days prior to Day 1.
* Topical treatments for AD (corticosteroids, calcineurin inhibitors, topical H1 and H2 antihistamines, topical antimicrobials, and other medicated topical agents) within 2 weeks prior to Day 1.
* Live attenuated vaccine treatment within 12 weeks prior to Day 1.
* Other investigational product within 30 days or 5 half-lives (whichever is longer) prior to Day 1.
7. Previous failure to respond to prior therapy with JAK inhibitors (systemic or topical), as determined by the investigator.
8. Current use of an oral H1 antihistamine (e.g., diphenhydramine, terfenadine) unless the patient is on a stable dose for at least 14 days prior to the Screening Visit.
9. Medical marijuana unless the patient is on a stable dose for at least 14 days prior to the Screening Visit.
10. Clinically significant laboratory abnormalities at the Screening Visit that, in the opinion of the investigator, could affect interpretation of study data or the safety of the patient's participation in the study.
11. Clinical laboratory values:
* White blood cell count \<2×109/L
* Absolute neutrophil count (ANC) \<1800/mL
* Platelet count \<130,000/mL
* Hemoglobin \<8g/dL
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2× the upper limit of normal
* Lymphocyte count \<0.5×109/L
12. Investigator-assessed history of, or current physical findings of, severe, progressive, or uncontrolled immunologic, hepatic, gastrointestinal, pulmonary, cardiovascular, genitourinary (renal), hematological, neurologic or cerebral disorders, infectious disease or coagulation disorders that, as determined by the investigator, could affect the safety of the patient's participation in the study or would preclude participation in and completion of study assessments.
13. History of, current, or suspected systemic or cutaneous malignancy and/or lymphoproliferative disease within the last 5 years, other than patients with a history of adequately treated and well healed and completely cleared nonmelanoma skin cancers (i.e., basal or squamous cell carcinoma) or cervical carcinoma in situ treated successfully at least 1 year prior to the Screening Visit 1 with no evidence of disease.
14. Evidence of active, chronic, or latent infections at the time of enrollment or a systemic infection including but not limited to a history of treated infection (e.g., pneumonia, septicemia) within 3 months prior to Day 1.
15. Patient has a known active or history of incompletely treated or untreated active tuberculosis. Patients with a history of active tuberculosis must have documented adequate treatment verified by the investigator. Patients who demonstrate evidence of latent tuberculosis infection (positive QuantiFERON® Tuberculosis Gold Test) will only be allowed to participate in the study if there is documented evidence of a completed adequate treatment course for latent tuberculosis and if active tuberculosis is excluded per the investigator's judgment.
16. History of a serious local skin infection (e.g., cellulitis, abscess) within 5 years of the Screening Visit.
17. Positive serological test for human immunodeficiency virus (HIV) (antibody), hepatitis C virus (antibody), hepatitis B surface antigen, or hepatitis B core antigen antibody.
18. Known significant exposure (close contact \[\<6 feet\] for ≥15 minutes) to an individual with a confirmed diagnosis of coronavirus disease 2019 (COVID-19) at any time during the Screening Period.
19. Herpes zoster or cytomegalovirus infection that resolved less than 2 months prior to the Screening Visit. Patients with a history of frequent outbreaks of herpes simplex virus (defined as 4 or more outbreaks a year).
20. Clinically significant electrocardiogram (ECG) findings such as, but not limited to, baseline mean QTcF \>450 msec for males or \>470 msec for females (use of the ECG algorithm is acceptable for this purpose).
21. Known allergy to any of the inactive ingredients in the study drug.
22. Female patients who are pregnant, nursing, or planning to become pregnant during the study.
23. Legal incapacity or limited legal capacity.
24. Major surgery within 3 months of the Screening Visit.
25. Any other condition that precludes adequate understanding, cooperation, and compliance with study procedures or any condition that could pose a risk to the patient's safety, as per the investigator's judgment.
2. Refractory AD (i.e., AD that required frequent hospitalizations and/or frequent intravenous treatment for skin infections within the year before the Screening Visit).
3. AD of a severity (EASI \>48) that the patient is not a candidate for a vehicle-controlled study.
4. Any signs or symptoms associated with AD therapy (e.g., history of anaphylaxis, hypersensitivity reactions, skin atrophy, striae, pigmentary changes) that, in the investigator's opinion, might impair evaluation of the AD or which exposes the patient to unacceptable risk by study participation.
5. Concomitant skin disease or clinically infected AD or presence of other skin disease in the area to be dosed that may interfere with study assessments.
6. Use of any of the following treatments within the indicated washout period prior to Day 1:
* Phototherapy (ultraviolet A, ultraviolet B, or psoralen and ultraviolet A therapy) within 4 weeks prior to Day 1.
* Systemic biologic immunosuppressant or immunomodulatory therapy (e.g., etanercept, alefacept, infliximab, dupilumab) within 12 weeks (or 5 half-lives of the product, whichever is longer) prior to Day 1.
* Non-biologic immunosuppressants (e.g., methotrexate, retinoids, calcineurin inhibitors, cyclosporine, hydroxycarbamide \[hydroxyurea\], azathioprine) within 4 weeks prior to Day 1.
* Janus kinase (JAK) inhibitors (systemic and topical) within 4 weeks prior to Day 1.
* Systemic corticosteroids within 2 weeks prior to Day 1 (intranasal, inhaled, and topical ocular corticosteroids are allowed).
* Cytostatic agents within 4 weeks prior to Day 1.
* Crisaborole within 2 weeks prior to Day 1.
* Systemic antibiotics within 30 days prior to Day 1.
* Topical treatments for AD (corticosteroids, calcineurin inhibitors, topical H1 and H2 antihistamines, topical antimicrobials, and other medicated topical agents) within 2 weeks prior to Day 1.
* Live attenuated vaccine treatment within 12 weeks prior to Day 1.
* Other investigational product within 30 days or 5 half-lives (whichever is longer) prior to Day 1.
7. Previous failure to respond to prior therapy with JAK inhibitors (systemic or topical), as determined by the investigator.
8. Current use of an oral H1 antihistamine (e.g., diphenhydramine, terfenadine) unless the patient is on a stable dose for at least 14 days prior to the Screening Visit.
9. Medical marijuana unless the patient is on a stable dose for at least 14 days prior to the Screening Visit.
10. Clinically significant laboratory abnormalities at the Screening Visit that, in the opinion of the investigator, could affect interpretation of study data or the safety of the patient's participation in the study.
11. Clinical laboratory values:
* White blood cell count \<2×109/L
* Absolute neutrophil count (ANC) \<1800/mL
* Platelet count \<130,000/mL
* Hemoglobin \<8g/dL
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2× the upper limit of normal
* Lymphocyte count \<0.5×109/L
12. Investigator-assessed history of, or current physical findings of, severe, progressive, or uncontrolled immunologic, hepatic, gastrointestinal, pulmonary, cardiovascular, genitourinary (renal), hematological, neurologic or cerebral disorders, infectious disease or coagulation disorders that, as determined by the investigator, could affect the safety of the patient's participation in the study or would preclude participation in and completion of study assessments.
13. History of, current, or suspected systemic or cutaneous malignancy and/or lymphoproliferative disease within the last 5 years, other than patients with a history of adequately treated and well healed and completely cleared nonmelanoma skin cancers (i.e., basal or squamous cell carcinoma) or cervical carcinoma in situ treated successfully at least 1 year prior to the Screening Visit 1 with no evidence of disease.
14. Evidence of active, chronic, or latent infections at the time of enrollment or a systemic infection including but not limited to a history of treated infection (e.g., pneumonia, septicemia) within 3 months prior to Day 1.
15. Patient has a known active or history of incompletely treated or untreated active tuberculosis. Patients with a history of active tuberculosis must have documented adequate treatment verified by the investigator. Patients who demonstrate evidence of latent tuberculosis infection (positive QuantiFERON® Tuberculosis Gold Test) will only be allowed to participate in the study if there is documented evidence of a completed adequate treatment course for latent tuberculosis and if active tuberculosis is excluded per the investigator's judgment.
16. History of a serious local skin infection (e.g., cellulitis, abscess) within 5 years of the Screening Visit.
17. Positive serological test for human immunodeficiency virus (HIV) (antibody), hepatitis C virus (antibody), hepatitis B surface antigen, or hepatitis B core antigen antibody.
18. Known significant exposure (close contact \[\<6 feet\] for ≥15 minutes) to an individual with a confirmed diagnosis of coronavirus disease 2019 (COVID-19) at any time during the Screening Period.
19. Herpes zoster or cytomegalovirus infection that resolved less than 2 months prior to the Screening Visit. Patients with a history of frequent outbreaks of herpes simplex virus (defined as 4 or more outbreaks a year).
20. Clinically significant electrocardiogram (ECG) findings such as, but not limited to, baseline mean QTcF \>450 msec for males or \>470 msec for females (use of the ECG algorithm is acceptable for this purpose).
21. Known allergy to any of the inactive ingredients in the study drug.
22. Female patients who are pregnant, nursing, or planning to become pregnant during the study.
23. Legal incapacity or limited legal capacity.
24. Major surgery within 3 months of the Screening Visit.
25. Any other condition that precludes adequate understanding, cooperation, and compliance with study procedures or any condition that could pose a risk to the patient's safety, as per the investigator's judgment.
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aclaris Therapeutics, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aclaris Investigational Site
Scottsdale, Arizona, United States
Site Status
Aclaris Investigational Site
Encino, California, United States
Site Status
Aclaris Investigational Site
Los Angeles, California, United States
Site Status
Aclaris Investigational Site
Tampa, Florida, United States
Site Status
Aclaris Investigational Site
Indianapolis, Indiana, United States
Site Status
Aclaris Investigational Site
Overland Park, Kansas, United States
Site Status
Aclaris Investigational Site
Omaha, Nebraska, United States
Site Status
Aclaris Investigational Site
Kew Gardens, New York, United States
Site Status
Aclaris Investigational Site
Newtown Square, Pennsylvania, United States
Site Status
Aclaris Investigational Site
Fountain Inn, South Carolina, United States
Site Status
Aclaris Investigational Site
Austin, Texas, United States
Site Status
Aclaris Investigational Site
San Antonio, Texas, United States
Site Status
Aclaris Investigational Site
Lynchburg, Virginia, United States
Site Status
Aclaris Investigational Site
Newport News, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Changelian P, Xu C, Mnich S, Hope H, Kostecki K, Hirsch J, Loh CY, Anderson D, Blinn J, Hockerman S, Dick E, Smith W, Monahan J, Raoof T, Forman S, Burt D, Barnes B, Gordon D, Walker N, Sudzina J, Tucker S, Jacobsen J. ATI-1777, a Topical Jak1/3 Inhibitor, May Benefit Atopic Dermatitis without Systemic Drug Exposure: Results from Preclinical Development and Phase 2a Randomized Control Study ATI-1777-AD-201. JID Innov. 2023 Nov 28;4(2):100251. doi: 10.1016/j.xjidi.2023.100251. eCollection 2024 Mar.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATI-1777-AD-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT04875169
COMPLETED
PHASE3
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
NCT02002208
COMPLETED
PHASE2
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
NCT01756898
COMPLETED
PHASE2
A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis
NCT03689829
TERMINATED
PHASE1
A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis
NCT04256174
COMPLETED
PHASE1
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948
ACTIVE_NOT_RECRUITING
PHASE2
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
NCT07205081
RECRUITING
PHASE1
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT02277743
COMPLETED
PHASE3
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425
RECRUITING
PHASE2
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05999799
TERMINATED
PHASE2
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis
NCT00697710
COMPLETED
PHASE1/PHASE2
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822
COMPLETED
PHASE3
Sublingual Immunotherapy in Patients With Atopic Dermatitis
NCT01471119
COMPLETED
PHASE2
A Trial of Antroquinonol in Patients With Atopic Dermatitis
NCT03622463
COMPLETED
PHASE2
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
NCT07105488
RECRUITING
PHASE2
Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
NCT04717310
UNKNOWN
PHASE2/PHASE3
A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT04162899
COMPLETED
PHASE2
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
NCT06504160
RECRUITING
PHASE1/PHASE2
An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis
NCT02655679
COMPLETED
PHASE1/PHASE2
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
NCT03654755
TERMINATED
PHASE2
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
NCT06881251
ACTIVE_NOT_RECRUITING
PHASE2
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT02277769
COMPLETED
PHASE3
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578
ENROLLING_BY_INVITATION
PHASE2/PHASE3